The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
ApexOnco Front Page
Recent articles
16 July 2025
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
10 July 2025
Autogene cevumeran goes on hold in adjuvant bladder cancer.
9 July 2025
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
9 July 2025
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
9 July 2025
ESO-T01 delivers its first four multiple myeloma case reports.
8 July 2025
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
8 July 2025
PD-(L)1 x VEGF bispecifics prove a big draw.